Auricchio Angelo, Metra Marco, Gasparini Maurizio, Lamp Barbara, Klersy Catherine, Curnis Antonio, Fantoni Cecilia, Gronda Edoardo, Vogt Juergen
Division of Cardiology, University Hospital, Magdeburg, Germany.
Am J Cardiol. 2007 Jan 15;99(2):232-8. doi: 10.1016/j.amjcard.2006.07.087. Epub 2006 Nov 17.
This multicenter longitudinal observational trial was designed to analyze the long-term outcome of patients with heart failure (HF) treated with cardiac resynchronization therapy (CRT) alone or with implantable cardioverter-defibrillator (ICD) backup in a daily practice scenario. It is unknown whether the magnitude of survival benefits conferred by CRT in a daily practice scenario is comparable to what has been observed in randomized controlled trials and whether this benefit is sustained over the long term. The outcome of 1,303 consecutive patients with ischemic or nonischemic cardiomyopathy on optimal pharmacologic therapy treated from August 1, 1995 to August 1, 2004 at 4 European centers with CRT alone (44%) or with ICD backup for symptomatic HF and prolonged QRS duration was assessed. Cumulative event-free survival was evaluated for a combined end point, defined as death from any cause, urgent transplantation, or implantation of a left ventricular assist device. The cumulative incidence of competing events, HF, sudden cardiac death, and noncardiac death, was also assessed. Event-free survival was similar across the different centers. At 1 and 5 years, cumulative event-free survivals were 92% (95% confidence interval [CI] 91 to 94) and 56% (95% CI 48 to 64), respectively. The cumulative incidence of HF deaths was 25.1% (95% CI 19 to 31.7), whereas that of sudden death was 9.5% (95% CI 5.1 to 15.7). Using multivariate analysis, CRT with an ICD backup was associated with a nonsignificant decrease in mortality by 20% (hazard ratio 0.83, 95% CI 0.58 to 1.17, p = 0.284), with a highly significant protective effect against sudden cardiac death (hazard ratio 0.04, 95% CI 0.04 to 0.28, p <0.002). In conclusion, patients with advanced HF and a wide QRS complex routinely treated with CRT have a favorable long-term outcome that was reproducible at different centers. The leading cause of death in these patients remained HF, and this mode of death was competing with other causes in determining outcome. Total mortality was 20% lower with ICD backup (95% CI 42% lower to 17% higher) due to a protective effect against sudden cardiac death.
这项多中心纵向观察性试验旨在分析在日常临床实践中,单独接受心脏再同步治疗(CRT)或配备植入式心脏复律除颤器(ICD)作为备用治疗的心力衰竭(HF)患者的长期预后。目前尚不清楚在日常临床实践中CRT所带来的生存获益程度是否与随机对照试验中观察到的相当,以及这种获益是否能长期持续。对1995年8月1日至2004年8月1日期间在4个欧洲中心接受最佳药物治疗的1303例连续性缺血性或非缺血性心肌病患者进行了评估,这些患者单独接受CRT治疗(44%)或因症状性HF和QRS时限延长而配备ICD作为备用治疗。对一个综合终点进行累积无事件生存评估,该综合终点定义为任何原因导致的死亡、紧急移植或植入左心室辅助装置。还评估了竞争性事件、HF、心源性猝死和非心源性死亡的累积发生率。不同中心的无事件生存情况相似。在1年和5年时,累积无事件生存率分别为92%(95%置信区间[CI]91至94)和56%(95%CI48至64)。HF死亡的累积发生率为25.1%(95%CI19至31.7),而猝死的累积发生率为9.5%(95%CI5.1至15.7)。采用多变量分析,配备ICD作为备用治疗的CRT与死亡率非显著性降低20%相关(风险比0.83,95%CI0.58至1.17,p = 0.284),对心源性猝死具有高度显著的保护作用(风险比0.04,95%CI0.04至0.28,p <0.002)。总之,常规接受CRT治疗的晚期HF和宽QRS波群患者具有良好的长期预后,且在不同中心均可重现。这些患者的主要死亡原因仍是HF,且这种死亡方式在决定预后方面与其他原因相互竞争。由于对心源性猝死具有保护作用,配备ICD作为备用治疗时总死亡率降低20%(95%CI降低42%至升高17%)。